TXMD News and Press, TherapeuticsMD Inc. From 11/13/20

TherapeuticsMD, Inc. (NASDAQ:TXMD) today announced the closing of its underwritten public offering of 23,437,500 shares of its common stock for net proceeds of approximately $27.5 million, after deducting underwriting discounts and commissions and estimated offering expenses payable by ...

TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative women’s healthcare company, today announced that the company will participate in the Stifel 2020 Virtual Healthcare Conference. Details for the presentation include: A live webcast and replay of the presentation can be ac...

The following slide deck was published by TherapeuticsMD, Inc. in conjunction with their 2020 Q3 earnings call. For further details see: TherapeuticsMD, Inc. 2020 Q3 - Results - Earnings Call Presentation

TherapeuticsMD (TXMD) prices of its underwritten public offering of ~23.4M shares of its common stock for gross proceeds of $30M.Offering expected to close on or about November 12, 2020.Underwriters' option for additional 3.5M shares.Net proceeds to be used for commercialization of its t...

TherapeuticsMD, Inc. (NASDAQ:TXMD) today announced the pricing of its underwritten public offering of approximately 23.4 million shares of its common stock for gross proceeds of $30 million, before deducting the underwriting discounts and commissions and other estimated offering expense...

TherapeuticsMD (TXMD) down 12% after hours, after announcing an underwritten public offering of its common stock. Underwriters have an option to purchase up to an additional 15% of the number of shares of its common stock offered.Price, volume are yet to be determined. For fu...

TherapeuticsMD, Inc. (NASDAQ:TXMD) today announced an underwritten public offering of its common stock. The Company has granted the underwriter a 30-day option to purchase up to an additional 15% of the number of shares of its common stock offered in the offering. All of the shares in t...

Image source: The Motley Fool. TherapeuticsMD, Inc. (NASDAQ: TXMD) Q3 2020 Earnings Call Nov 09, 2020 , 8:30 a.m. ET Operator Continue reading For further details see: TherapeuticsMD, Inc. (TXMD) Q3 2020 Earnings Call Transcript

TherapeuticsMD, Inc. (TXMD) Q3 2020 Earnings Conference Call November 9, 2020 8:30 AM ET Company Participants Nichol Ochsner – Vice President of Investor Relations Robert Finizio – Chief Executive Officer James D’Arecca – Chief Financial Officer Dawn Halkuff ȁ...

TherapeuticsMD ([[TXMD]] +14.8%) Q3 results:Revenue of $19.3M (-18.5% Y/Y) vs consensus of $15.44M; Annovera revenue of $6.4M (+250% Q/Q).Imvexxy revenue (+35 Q/Q) to $6.8M.BIJUVA revenue (+22 Q/Q) to $1.6M.Gross margin increased to 83%, compared to 59% for the quarter end...